EDC Validation for Medical Device Trials: Part 11 and Data Integrity

Why EDC Validation Matters for Device Trials

Electronic Data Capture (EDC) systems are the backbone of modern clinical data collection. Over 80% of clinical trials worldwide now rely on EDC platforms to collect, manage, and transmit patient data from investigative sites to sponsors and contract research organizations. For medical device trials -- where clinical data often directly supports 510(k) substantial equivalence claims, De Novo classification requests, or PMA safety and effectiveness determinations -- the integrity of EDC data carries exceptionally high regulatory stakes.

FDA, EMA, and other global regulators expect validated EDC systems with complete, tamper-evident audit trails. Inadequate EDC validation consistently ranks among the most common findings in FDA inspections of clinical trials. When FDA investigators arrive at a sponsor site or CRO, they will examine whether the EDC system was properly validated, whether audit trails capture all data changes with reasons, whether electronic signatures meet Part 11 requirements, and whether the sponsor has maintained oversight of the system throughout the study lifecycle.

The consequences of validation failures are concrete. FDA can issue a Warning Letter citing Part 11 violations, which may delay or derail a device submission. Invalidated or unreliable clinical data can be excluded from a regulatory review, undermining years of trial work. For PMA submissions in particular, where clinical data is the centerpiece of the safety and effectiveness analysis, an FDA finding that the EDC system was inadequately validated can trigger a major amendment cycle, an advisory panel referral, or even a not-approvable decision.

Regulatory Framework

EDC validation sits at the intersection of several overlapping regulatory frameworks. Understanding each one -- and how they interact -- is essential for building a compliant validation strategy.

21 CFR Part 11: Electronic Records and Electronic Signatures

21 CFR Part 11 is the FDA regulation governing electronic records and electronic signatures in FDA-regulated activities. Enacted in 1997 and clarified through FDA's 2003 guidance on scope and application, Part 11 applies to any FDA-regulated entity -- including medical device sponsors -- that creates, modifies, maintains, archives, retrieves, or transmits electronic records in fulfillment of FDA requirements.

Part 11 establishes several core requirements directly relevant to EDC systems:

• Validated systems (21 CFR 11.10(a)): Systems must be validated to ensure accuracy, reliability, consistent intended performance, and the ability to discern invalid or altered records.

• Audit trails (21 CFR 11.10(e)): Secure, computer-generated, time-stamped audit trails that independently record the date and time of operator entries and actions that create, modify, or delete electronic records. Audit trails must not obscure previous values and must be available for agency review.

• Access controls (21 CFR 11.10(d)): Authority checks to ensure that only authorized individuals can access the system, enter data, alter data, or electronically sign records.

• Electronic signatures (21 CFR 11.50, 11.70): E-signatures must include the signer's printed name, the date and time, the meaning of the signature (such as "review," "approval," or "data entry"), and must be permanently linked to their corresponding electronic records so they cannot be excised or copied to falsify another record.

For medical device trials conducted under an IDE (21 CFR 812), Part 11 applies to all electronic records generated in the EDC system, including case report form data, query histories, audit trail entries, and electronic signatures applied by investigators, monitors, and data managers.

EU GMP Annex 11: Computerized Systems

EU GMP Annex 11 is the European regulatory framework for computerized systems used in GMP-regulated environments. While its primary application is pharmaceutical manufacturing, Annex 11 principles apply broadly to any computerized system handling regulated clinical data in the EU, including EDC systems used in medical device clinical investigations conducted under EU MDR requirements.

Annex 11 requires risk-based validation of computerized systems based on their intended use and potential impact on product quality and data integrity. Key provisions include:

• Validation must demonstrate that the system meets its intended purpose and that risks have been assessed and mitigated.

• Audit trails must be enabled for all GMP-relevant data changes, capturing the old value, new value, who made the change, when, and why.

• Data must be secured against accidental or unauthorized alteration, loss, or damage.

• System access must be controlled through individual login credentials with appropriate role-based permissions.

Annex 11 also introduces the concept of "data integrity by design," requiring that systems be designed to prevent data integrity failures rather than relying solely on detection after the fact.

ICH E6(R2)/(R3): Good Clinical Practice

ICH E6 is the international Good Clinical Practice (GCP) guideline that sets standards for the design, conduct, recording, and reporting of clinical trials. Section 5.5 of ICH E6(R2) specifically requires sponsors to use validated, SOP-driven systems for handling clinical data, with appropriate controls to ensure data quality and integrity.

The updated ICH E6(R3), finalized by ICH in January 2025 and adopted by the EMA (effective July 2025), modernizes GCP expectations for electronic systems. E6(R3) includes a new section on data governance that directly addresses the use of computerized systems in clinical trials. Key provisions relevant to EDC validation include:

• Sponsors must demonstrate that trial-specific computerized systems are validated for their intended use.

• Non-trial-specific systems (such as electronic health records serving as source data) must be assessed as fit for purpose.

• Data governance frameworks must address data integrity, metadata management, and audit trail requirements throughout the data lifecycle.

• The guideline explicitly addresses electronic source data, remote monitoring, and decentralized trial elements -- all of which rely heavily on EDC systems.

FDA released its draft guidance adopting ICH E6(R3) in September 2025. While ICH E6(R3) represents the FDA's current thinking, the agency notes that the guideline is not binding. Nevertheless, sponsors should expect FDA inspections to increasingly reference E6(R3) principles as the standard of care evolves.

FDA October 2024 Guidance: Electronic Systems in Clinical Investigations

On October 2, 2024, FDA finalized its guidance document titled "Electronic Systems, Electronic Records, and Electronic Signatures in Clinical Investigations: Questions and Answers." This guidance provides practical, detailed answers to 29 questions covering electronic records, electronic systems deployed by regulated entities, IT service providers, digital health technologies, and electronic signatures.

Key takeaways from this guidance for EDC validation:

• FDA reiterates that Part 11 compliance is required for any electronic system once clinical data enters sponsor records, including EDC systems.

• FDA endorses a risk-based approach to validation, consistent with the 2003 Part 11 guidance -- meaning validation rigor should be proportional to the system's impact on data quality and patient safety.

• The guidance clarifies that electronic health record (EHR) systems used as source data are not subject to Part 11 validation by the sponsor, but sponsors must verify that EHR data copied into the EDC is accurate and complete.

• FDA expects regulated entities to retain electronic records, including audit trail data, for the duration required by applicable regulations, even when using cloud computing services.

FDA CSA Guidance (September 2025): Computer Software Assurance

On September 24, 2025, FDA released its final guidance on Computer Software Assurance (CSA) for Production and Quality System Software, which was subsequently updated on February 3, 2026 to align with the Quality Management System Regulation (QMSR). The guidance introduces a modern, risk-based approach to validating software used in manufacturing and quality systems, superseding the legacy General Principles of Software Validation (GPSV) framework from 2002.

The CSA guidance is relevant to EDC validation in two ways:

First, it establishes a philosophical shift toward intended use plus risk as the organizing principle for software assurance. Rather than requiring exhaustive scripted testing of every function, CSA encourages sponsors to focus validation effort on features and functions that directly impact product quality, data integrity, and patient safety. This "least burdensome" approach is consistent with how many sponsors already approach EDC validation in practice.

Second, the CSA guidance explicitly states that it does not change Part 11 requirements. Part 11's mandates for validated systems, audit trails, access controls, and electronic signatures remain fully in effect. CSA only changes how sponsors demonstrate compliance -- emphasizing critical thinking and risk-based evidence over rote documentation.

GAMP 5 Second Edition (2022)

ISPE's GAMP 5: A Risk-Based Approach to Compliant GxP Computerized Systems (Second Edition, published 2022) is the industry-standard framework for computerized system validation across the life sciences. While GAMP 5 is not a regulatory requirement itself, it is widely recognized by FDA inspectors, EU auditors, and other global regulators as representing best practices for validation.

The Second Edition updates the original GAMP 5 framework with modern guidance on cloud computing, agile development methodologies, AI and machine learning systems, open-source software, and expanded data integrity requirements. The industry is expected to achieve full alignment with GAMP 5 Second Edition by August 2026.

GAMP 5 Second Edition emphasizes:

• Critical thinking over prescriptive documentation -- validating the right things, not everything.

• Scalable lifecycle activities -- validation effort should match the complexity and risk of the system.

• Leveraging supplier involvement -- using vendor documentation, test results, and certifications to reduce duplicative sponsor effort.

• Data integrity by design -- embedding ALCOA+ principles into system requirements and validation activities.

GAMP 5 Software Categories and EDC

GAMP 5 classifies software and hardware into categories based on configurability and customization, which directly determines the validation approach and effort required. Understanding where your EDC system fits is the starting point for any validation project.

Most commercially available EDC systems fall into Category 4: they are standard products that the sponsor configures to meet study-specific requirements (building eCRFs, programming edit checks, defining user roles, setting up workflows). This means the sponsor must validate their specific configuration while leveraging the vendor's platform qualification documentation for the underlying base system.

A custom-built EDC system would be Category 5 and requires substantially more validation effort, including full requirements specifications, design specifications, code reviews, unit testing, integration testing, and user acceptance testing -- essentially the complete SDLC.

The V-Model and IQ/OQ/PQ for EDC

The V-Model remains the dominant validation lifecycle framework for EDC systems. It maps user requirements to corresponding test activities in a "V" shape: requirements specification flows down the left side through functional specifications and design, and verification and testing flow back up the right side. The model ensures that every requirement is linked to a test that demonstrates it has been met.

For EDC validation, the V-Model is applied through three qualification phases.

Installation Qualification (IQ)

IQ verifies that the EDC system is installed correctly in its operational environment and that the infrastructure meets documented specifications. IQ is primarily about confirming the deployment matches the design.

Typical IQ activities for an EDC system include:

• Verify that server hardware and software (operating system, database engine, application server) match documented specifications.

• Confirm that the correct version of the EDC application is installed, including any patches or updates.

• Document network configuration, including connectivity between application servers, database servers, and client access points.

• Verify that the cloud environment (if applicable) meets security and availability requirements, including encryption, backup, and disaster recovery configurations.

• Confirm that all interfaces with external systems (CTMS, IRT, safety databases, ePRO platforms) are correctly configured.

• Document the system configuration baseline, including server settings, security configurations, and database parameters.

• Verify that user account creation and role assignment procedures are functional.

Operational Qualification (OQ)

OQ tests all functional requirements of the EDC system in its configured state. This is where the bulk of Part 11-relevant testing occurs. OQ must demonstrate that the system operates as intended under normal and boundary conditions.

Typical OQ test areas for an EDC system include:

• Audit trail testing: Verify that all data changes (create, modify, delete) generate complete audit trail entries capturing who, when, old value, new value, and reason for change. Test that audit trails cannot be modified or deleted by any user, including system administrators.

• User access controls: Verify that role-based access works correctly -- that users can only perform actions within their assigned role (e.g., investigators can enter data but not lock the database; monitors can review but not modify source data).

• Electronic signature functionality: Test that e-signatures meet all Part 11 requirements, including signer identification, date/time stamping, signature meaning, and inextricable linkage to the signed record. Verify that e-signatures cannot be forged, copied, or repudiated.

• Edit check programming: Test every programmed validation rule with both valid data (pass case) and invalid data (fail case) to confirm the rule fires correctly and generates the expected query or error message.

• Data integrity controls: Test boundary conditions (minimum and maximum values, date ranges, required fields), negative tests (entering alphabetic characters in numeric fields, out-of-range dates, duplicate entries), and data export accuracy.

• Workflow testing: Verify that data review, query management, data locking, and database freeze/unfreeze functions operate correctly.

• Session management: Test automatic session timeouts, concurrent login restrictions, and password complexity requirements.

Performance Qualification (PQ)

PQ demonstrates that the EDC system performs reliably in the hands of real users executing real processes under production conditions. PQ is essentially user acceptance testing (UAT) conducted by the study team.

Typical PQ activities include:

• End-to-end workflow testing: A representative group of users (investigators, coordinators, monitors, data managers) executes complete data entry, review, query, correction, and signature workflows using realistic test data that mirrors the planned study.

• Data extraction verification: Confirm that data extracted from the EDC system matches the data entered, including all metadata, audit trail entries, and signature records. This is critical for demonstrating that the analysis dataset is a faithful representation of the captured clinical data.

• Multi-site simulation: For multi-center trials, test that site-level data segregation, user permissions, and site-specific configurations function correctly.

• Load and performance testing: Verify that the system maintains acceptable response times under expected concurrent user loads.

Requirements Traceability Matrix

The Requirements Traceability Matrix (RTM) is the single most important document in any EDC validation project. It links every requirement in the User Requirements Specification (URS) to the specific test case(s) that verify it, and traces through to the test results and the validation summary conclusion.

A well-constructed RTM allows any auditor or inspector to trace a path from a regulatory requirement (such as "the system must generate audit trails for all data modifications" from 21 CFR 11.10(e)) through the URS requirement, to the functional specification, to the specific OQ test case, to the test result, and to the final validation conclusion.

Typical IQ/OQ/PQ Test Cases for EDC

Audit Trail Requirements

Audit trails are the centerpiece of Part 11 compliance and the single most scrutinized element in FDA inspections of EDC systems. An EDC system without a complete, tamper-evident audit trail is, for regulatory purposes, no better than an uncontrolled paper notebook.

Core Audit Trail Requirements

Under 21 CFR 11.10(e), audit trails must be:

• Computer-generated: Not dependent on manual entry or user action to capture changes.

• Time-stamped: Each entry must include a precise date and time.

• Secure: Audit trail data must be protected from modification, deletion, and unauthorized access.

• Independently recorded: The audit trail must be a separate, traceable record -- not simply a log stored within the same data table it monitors.

• Available for review: FDA investigators must be able to review audit trail data throughout the study, not just at the end.

Each audit trail entry must capture four essential elements:

1. Who made the change (unique user identification).

2. When the change was made (precise date and time).

3. What changed (the old value and the new value).

4. Why the change was made (reason for change).

The reason-for-change requirement is one of the most commonly cited deficiencies in FDA inspections. Many EDC systems can be configured to require a reason for change, but if this feature is not enabled and enforced, the audit trail will be incomplete.

ALCOA+ Principles

The ALCOA+ framework defines nine principles for data integrity that apply to all clinical trial records, including EDC data and audit trails. FDA, MHRA, WHO, and PIC/S have all adopted ALCOA+ as the standard for evaluating data integrity.

Audit Trail Review Procedures

FDA and EU regulators increasingly expect proactive, ongoing audit trail review -- not just a dump of the audit trail at the end of the study. Audit trail review should be risk-based and integrated into routine monitoring and data management activities.

Best practices for audit trail review include:

• Define review frequency in the Data Management Plan or monitoring plan -- monthly, quarterly, or per monitoring visit, depending on study risk.

• Focus on high-risk changes: modifications to primary endpoint data, safety data, and informed consent records.

• Check for patterns: unusual volumes of changes from specific sites or users, changes made outside normal business hours, changes without adequate reasons, or systematic data alterations.

• Document review findings: maintain a log of audit trail reviews performed, issues identified, and corrective actions taken.

• Train the review team: monitors and data managers must understand what to look for and how to evaluate audit trail data.

Timestamp Controls

Timestamp integrity is essential. EDC systems should:

• Use UTC (Coordinated Universal Time) or record timestamps with an explicit timezone offset.

• Prevent users from modifying the system date/time.

• Synchronize server clocks with a reliable time source (such as NTP).

• Log all timestamp metadata, including timezone, in audit trail entries.

Vendor vs Sponsor Responsibilities

One of the most frequently misunderstood aspects of EDC validation is the division of responsibility between the EDC vendor and the sponsor (or CRO acting on the sponsor's behalf). The fundamental principle is clear: the sponsor holds ultimate regulatory responsibility for data integrity, and this responsibility cannot be fully delegated to the vendor.

Vendor Responsibilities

The EDC vendor (Medidata, Oracle, Veeva, Castor, or other provider) is responsible for qualifying their base platform. This includes:

• Validating the core EDC platform software (base platform IQ/OQ).

• Conducting security testing and vulnerability assessments.

• Performing performance and load testing.

• Managing the software development lifecycle, including change control for platform updates.

• Providing validation documentation, including Installation Qualification certificates, functional specifications, and release notes.

• Maintaining SOC 2 Type II compliance (or equivalent) for cloud-hosted platforms.

• Conducting regular penetration testing and maintaining disaster recovery capabilities.

Sponsor Responsibilities

The sponsor is responsible for validating the EDC system as configured for their specific study. This includes:

• Preparing the User Requirements Specification (URS) for the study-specific configuration.

• Conducting a risk assessment of the configured system.

• Performing IQ/OQ/PQ on the study-specific build (the eCRFs, edit checks, user roles, and workflows configured for the trial).

• Verifying that audit trail settings are enabled and configured correctly.

• Testing electronic signature functionality in the sponsor's operational environment.

• Conducting User Acceptance Testing (UAT) with the actual study team.

• Maintaining the validation documentation package throughout the study lifecycle.

• Managing change control for any modifications to the EDC configuration during the study.

• Assessing and auditing the vendor's quality system and validation practices.

Responsibility Matrix

Leveraging Vendor Evidence

Sponsors do not need to re-test functions that the vendor has already thoroughly tested and documented. GAMP 5 Second Edition explicitly encourages leveraging supplier documentation. Practical steps include:

• Obtain and review the vendor's validation summary report for the current platform version.

• Request the vendor's functional specification and traceability documentation.

• Review the vendor's SOC 2 Type II report for evidence of security and operational controls.

• Verify that the vendor's quality system includes adequate change control and release testing.

• Assess whether the vendor's validation covers all Part 11-relevant functions (audit trails, e-signatures, access controls).

The sponsor's validation can then focus on what is unique to the sponsor's configuration: the eCRF design, edit checks, user roles, workflows, and data extraction processes.

Study-Specific EDC Validation

Study-specific validation is where the sponsor demonstrates that the EDC system, as configured for a particular clinical trial, meets all study requirements and Part 11 obligations. This is distinct from (and builds upon) the vendor's base platform qualification.

eCRF Design Verification

Every electronic case report form (eCRF) must be verified against the protocol, the Data Management Plan, and the annotated eCRF to confirm that:

• All protocol-required data points are captured.

• Data field types, lengths, and formats match the specifications.

• Units of measure are correct and consistent.

• Visit schedules and form assignments match the protocol schedule of assessments.

• Missing data rules and required field settings are correctly implemented.

Edit Check Testing

Edit checks (also called validation rules or data validation checks) are programmed logic that verifies data quality at the point of entry. Every edit check must be tested with both valid and invalid data to confirm it fires correctly and generates the expected query or error message.

For a typical medical device pivotal study with 150-300 programmed edit checks, each check requires at least two test cases (pass and fail), plus boundary condition tests where applicable. This means 400-900 individual test executions, which must be documented with screenshots, expected results, and actual results.

Electronic Signature Testing

21 CFR Part 11 electronic signature testing must verify:

• Each e-signature includes the signer's printed name, date and time, and meaning of the signature.

• E-signatures are permanently linked to the signed record and cannot be excised, copied, or transferred to falsify another record.

• The system requires re-authentication (such as re-entry of user ID and password) at the time of signing.

• Signature manifestations appear on printed or displayed copies of the signed record.

• Failed signature attempts are logged.

Data Migration and Transfer Validation

When clinical data moves from the EDC system to the analysis database or statistical computing environment, the transfer process must be validated. This includes:

• Verifying that all data fields transfer completely and accurately.

• Confirming that audit trail data, query histories, and signature metadata are included or accessible.

• Validating data transformation rules (such as unit conversions, derivations, and coding to MedDRA or other dictionaries).

• Performing reconciliation between source and destination datasets.

Multi-Language Verification

For global medical device trials conducted across multiple countries, the EDC system may need to support multiple languages. Validation must verify that:

• Translations are accurate and culturally appropriate.

• Edit check messages appear in the correct language for each user.

• Data entry fields accept language-specific characters where applicable.

• Audit trail entries are captured consistently regardless of the user's language setting.

UAT Process

User Acceptance Testing is the final validation step before the EDC system goes live for a study. UAT should be conducted by the actual study team members who will use the system, including:

• Investigators and study coordinators (testing data entry workflows).

• Clinical research associates / monitors (testing data review and query workflows).

• Data managers (testing data cleaning, coding, and extraction workflows).

• Biostatisticians (testing data extraction and analysis readiness).

UAT sign-off should include formal documentation that each tester has executed their assigned test cases, confirmed that results meet acceptance criteria, and approved the system for production use.

EDC System Selection Criteria

Selecting the right EDC platform is a strategic decision that affects validation effort, trial timelines, and regulatory risk. The following criteria should be evaluated during EDC selection for medical device clinical trials.

Key Selection Criteria

• Part 11 compliance readiness: Does the vendor provide comprehensive validation documentation, audit trail functionality, and electronic signature capability that meets current Part 11 requirements?

• Audit trail capabilities: Are audit trails enabled by default? Can they be configured to require reasons for change? Are they tamper-evident and available for export and review?

• Electronic signature implementation: Do e-signatures meet all Part 11 requirements (signer identification, timestamp, meaning, linkage to record)?

• Data encryption standards: Is data encrypted at rest and in transit? What encryption standards are used?

• Scalability: Can the platform handle the complexity of your study, including the number of sites, subjects, data points, and visit schedules?

• Integration capabilities: Does the EDC integrate with CTMS, IRT, ePRO, safety databases, and other systems in your clinical technology ecosystem?

• Vendor support and training: What level of implementation support, training, and ongoing technical support does the vendor provide?

• Total cost of ownership: What are the licensing fees, implementation costs, per-site costs, and ongoing maintenance costs?

EDC Vendor Comparison

Common FDA Inspection Findings

Understanding the most frequent FDA inspection findings related to EDC validation helps sponsors focus their efforts on the areas that matter most to regulators. In 2025, the three most cited qualification gaps in FDA 483 observations were: retroactive documentation (validation performed after the system went live), missing requirements traceability matrix (RTM) linking test cases to user requirements, and absent Part 11 test cases in operational qualification. Change control gaps — where patches, upgrades, or configuration changes bypass formal Part 11 impact assessment — appeared in over 28% of Part 11-related 483s in 2025. The following sections detail the most commonly cited deficiencies.

Incomplete Audit Trails

The single most common finding. Audit trails that do not capture reason-for-change entries, that allow users to modify or delete audit trail data, or that are not enabled for all data modifications. FDA inspectors specifically check that audit trails are active for all GCP-relevant data changes, not just a subset.

Retroactive Documentation

Validation documentation dated after the system went live. FDA inspectors compare validation report dates against system go-live dates and first data entry dates. If the EDC system was in production use before validation was completed, this is a critical finding regardless of the quality of the eventual validation.

Missing Requirements Traceability

Validation test cases that cannot be traced back to specific user requirements or regulatory requirements. Without a complete RTM, FDA cannot verify that all Part 11 requirements have been tested, and the validation is considered incomplete.

Absent Part 11 Test Cases

OQ protocols that test functional requirements but omit specific Part 11 test cases for audit trails, electronic signatures, access controls, and system security. This is particularly common when sponsors rely heavily on vendor documentation without supplementing it with study-specific Part 11 testing.

Inadequate Vendor Assessment

Sponsors who use an EDC system without conducting any assessment of the vendor's quality system, validation practices, or compliance posture. FDA expects sponsors to have documentation demonstrating that they evaluated the vendor's capabilities and determined them to be adequate for the intended use.

Failure to Re-Validate After Updates

EDC systems are regularly updated by vendors to add features, fix bugs, and address security vulnerabilities. Each update potentially changes the validated state of the system. Sponsors who apply updates without assessing the impact on validation and performing appropriate re-testing receive findings. The assessment does not need to result in full re-validation for every update, but it must be documented and risk-based.

Shared User Accounts and Inadequate Access Controls

Sites or sponsors where multiple users share a single login credential, defeating individual accountability for data changes. Also cited: user accounts with excessive privileges, failure to revoke access for departed personnel, and lack of role-based access controls. Individual user accountability is a foundational requirement of both Part 11 and GCP.

Validation Documentation Package

A complete EDC validation documentation package includes the following documents, each serving a specific purpose in the validation lifecycle.

Document Checklist

All validation documents should be controlled under the organization's document control procedures, with formal review, approval, version control, and retention in the Trial Master File or validation archive.

Key Takeaways

• EDC validation is not optional. FDA, EMA, and global regulators require validated EDC systems for all clinical trials generating data for regulatory submissions. Inadequate validation is one of the most common FDA inspection findings and can jeopardize device approvals.

• Part 11 requirements are unchanged by CSA. The FDA's Computer Software Assurance guidance (issued September 2025, updated February 2026) changes how sponsors approach validation effort allocation, but it does not alter any Part 11 requirements for audit trails, electronic signatures, access controls, or system validation.

• Use GAMP 5 Second Edition as your framework. Most commercially available EDC systems are GAMP Category 4 (Configured Products). Leverage vendor platform qualification documentation and focus your validation effort on your study-specific configuration -- eCRFs, edit checks, workflows, and user roles.

• Audit trails must be complete, tamper-evident, and proactively reviewed. Every data change must be captured with who, when, what (old and new values), and why. Enable reason-for-change requirements in your EDC configuration and integrate audit trail review into routine monitoring activities.

• Sponsor responsibility cannot be delegated to the vendor. The vendor qualifies the platform; the sponsor validates the study-specific configuration. Document your vendor assessment, maintain your own validation package, and never assume vendor documentation alone satisfies your regulatory obligations.

• Build and maintain a complete Requirements Traceability Matrix. The RTM is the backbone of a defensible validation. Every requirement -- from Part 11 compliance to study-specific edit checks -- must trace to a test case, a test result, and a validation conclusion.

• Plan for the full lifecycle, including updates and retirement. Validation is not a one-time event. Establish change control procedures for system updates, conduct impact assessments for every vendor release, and plan for data preservation and access when the system is decommissioned at study end.